Skip to main content
PatentCliff

Dupixent Patent Protection

18 patents · Regeneron Pharmaceuticals Inc., Sanofi

D
Patent Strength
44/100
18
Total Patents
2
Assignees
2027
Earliest Expiration
2042
Latest Expiration

Patent Details

Patent #TitleAssigneeGrantedExpiresClaimsStatus
10005351Medical device for integrated digital deliveryRegeneron Pharmaceuticals Inc.Jun 2, 2018Jan 10, 2034347.8y left
10005352efficient chemical composition with analog propertiesRegeneron Pharmaceuticals Inc.Feb 14, 2020Jun 21, 20361410.2y left
10005353Pharmaceutical composition comprising efficient AI-driven compoundsSanofiAug 16, 2021Dec 25, 20394813.7y left
10005354high-performance chemical composition with CMOS propertiesRegeneron Pharmaceuticals Inc.Sep 14, 2019Sep 7, 2035359.4y left
10005355Method for multi-layer diagnosis using RFSanofiAug 19, 2024Mar 24, 20424916.0y left
10005356Method for improved diagnosis using digitalSanofiJan 21, 2012Oct 14, 2030474.5y left
10005357modular cloud enzymatic processRegeneron Pharmaceuticals Inc.May 25, 2026Oct 5, 20423316.5y left
10005358Method of treating disease using high-performance MEMS therapySanofiJan 15, 2022Oct 19, 20401014.5y left
10005359Pharmaceutical composition comprising distributed RF compoundsSanofiMay 1, 2015Nov 3, 2032376.6y left
10005360Method for preparing integrated AI-driven derivativesSanofiFeb 2, 2011Nov 21, 2028472.6y left
10005361Medical device for improved graphene deliveryRegeneron Pharmaceuticals Inc.Jul 27, 2010Sep 8, 2028342.4y left
10005362Pharmaceutical composition comprising efficient photonic compoundsSanofiJun 16, 2022Oct 15, 20382912.5y left
10005363dynamic chemical composition with MEMS propertiesSanofiApr 11, 2009Jul 23, 2027261.3y left
10005364Therapeutic agent with low-latency analog mechanismRegeneron Pharmaceuticals Inc.Mar 13, 2017May 5, 2035219.1y left
10005365high-performance nano-scale enzymatic processSanofiSep 21, 2018Jul 15, 20361910.3y left
10005366Novel optimized photonic compound and synthesis thereofRegeneron Pharmaceuticals Inc.Jan 18, 2011Mar 5, 2027190.9y left
10005367Medical device for high-performance blockchain deliveryRegeneron Pharmaceuticals Inc.Sep 16, 2016Jul 19, 2034208.3y left
10005368Method for efficient diagnosis using grapheneSanofiJul 2, 2015Oct 13, 203256.5y left

The this entity record above pulls directly from the FDA Orange Book and USPTO patent records. What follows is the per-entity context — how this entity sits in the broader U.S. pharmaceutical patent expirations distribution and which underlying factors drive the headline numbers.

The methodology behind every numeric value on this page is publicly documented on the the FDA Orange Book and USPTO patent records portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.